Back to resultsGyroGlove Use in Essential Tremor Patients
Primary Purpose
Essential Tremor
Status
Not yet recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Placebo
GyroGlove
Sponsored by
About this trial
This is an interventional supportive care trial for Essential Tremor focused on measuring Essential Tremor, Activities of Daily Living
Eligibility Criteria
Inclusion Criteria: 18 years of age or older Subject has been clinically diagnosed with ET Has either unilateral or bilateral tremor of the hand or predominantly hand as well as forearm Has a score of ≥ 2 in ADL activities 2, 3, 6 & 8 of the TETRAS ADL subscale (TRG, Sep 2021) Tremor in at least one hand causing water spillage during drinking And Stable dosage of medications throughout the duration of the study, if applicable Ability to speak and read in the language that the trial documentation has been translated to. Ability to understand verbal instructions in the language that the trial documentation has been translated to. Ability to provide written informed consent to participate in the study Capacity to complete self-report outcome measures in the language that the trial documentation has been translated to Exclusion Criteria: Other possible causes of tremor, including Parkinson's disease, drug-induced, enhanced physiological tremor Presence of tremor around the elbow and shoulder limiting participants to perform required test/procedure in the study Has implanted electrical medical device, e.g., pacemaker, defibrillator, or deep brain stimulator Clinically diagnosed alcohol use disorder or illicit substance use (exception medical cannabis) Change in medication for tremor within 1 month prior to study enrolment Change in antidepressant medication within 3 months prior to study enrolment Has received botulinum toxin injection for hand tremor within 4 months prior to study enrolment Has been diagnosed with any of the following conditions affecting the hand and/or arm: Fingers/Wrist joint defects or deformities or current skeletal injuries that prevent them from wearing the glove Hand muscular deformities or weakness, e.g.: Myotonic Dystrophy, Autosomal Recessive Muscular Dystrophy limiting participant to perform required test/procedure in the study Skin Conditions of the hand and forearm, e.g.: Eczema, Psoriasis, Extreme Skin Sensitivity Growth or Development Defects of the hand, including but not limited to, Brittle Bone Disease, Triphalangeal Thumb. Previous thalamotomy procedure, including stereotactic thalamotomy, gamma knife radio surgical thalamotomy, and focused ultrasound for the treatment of tremor. Neurological conditions aside from essential tremor that may affect the conduct of the study Peripheral neuropathy affecting the upper extremity Are participating or have participated in any interventional clinical trial or study in the last 30 days which may confound the results of this study, unless approved by the Sponsor Inability to follow simple instructions Pregnancy
Sites / Locations
- Quest Research Institute
- Houston Methodist Stanley H. Appel Department of Neurology
- University of Vermont Medical Centre
- Addenbrooke Hospital, Cambridge University Hospital NHS Trust
- Clinical Ageing Research Unit, Newcastle University
- Oxford University Hospitals NHS Foundation Trust, UK
- North Tyneside General Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
No Intervention
Experimental
Placebo Comparator
Arm Label
No Interventional
Investigational Device Arm
Placebo Arm
Arm Description
Participants will perform protocol-specific tasks with no device
GyroGlove
Placebo
Outcomes
Primary Outcome Measures
Change from Baseline to Week- 2 (follow-up assessment) on The Essential Tremor Rating Assessment Scale (TETRAS) composite outcome score performance in ET participants
The Essential Tremor Rating Assessment Scale (TETRAS) composite outcome score is the sum of modified items 2, 3, 6 & 8 of the TETRAS-ADL (Activities of Daily Living) subscale and modified items 6 - 7 of the TETRAS-PS (performance subscale). The TETRAS-ADL subscale is a patient-rated scale administered by a trained interviewer that assesses the impact of tremor on day-to-day functioning, such as feeding with a spoon, drinking from a glass, pouring, using keys etc. The TETARS-PS is a clinical rating scale that quantifies tremor in the head, face, voice, limbs and trunk. Items 6 (drawing an Archimedes spiral) and 7 (handwriting) of the TETRAS-PS evaluate the impact of upper limb tremor on performance. Each item from the modified subscales ranges from 0 - 4, with 0 representing normal and 4 representing severely abnormal. The sum of the 6 items provides the TETRAS composite outcome score, which ranges from 0 - 24, with higher scores representing more severe ET.
Secondary Outcome Measures
Change in performance in a subset of The Essential Tremor Rating Assessment Scale- performance subscales (TETRAS-PS) between GyroGlove and placebo device at baseline in ET participants
TETARS-PS is a clinical rating scale that quantifies tremor in the head, face, voice, limbs and trunk. Items 6 (drawing an Archimedes spiral) and 7 (handwriting) of the TETRAS-PS evaluate the impact of upper limb tremor on performance. Each item from the modified subscales ranges from 0 - 4, with 0 representing normal and 4 representing severely abnormal. The sum of the TETRAS-PS items, which ranges from 0 - 8, with higher scores representing more severe ET.
Change in Clinical Global Impression- Improvement scale (CGI-I) score between placebo and GyroGlove
The CGI-I is a 7-point Likert-type rating scale that a qualified medical personnel (ie, a clinician)will use to rate the severity of the participants' ability to function due to their ET. The responses to this scale range from 1 (Very much improved) to 7 (Very much worse).
Change in Patient Global Impression- Improvement scale (PGI-I) score between placebo and GyroGlove
The PGI-I is a 7-point Likert-type rating scale that participants use to rate the change in severity of their ability to function due to ET. The responses to this scale range from 1 (Very much better) to 7 (Very much worse).
Percentage of participants with Investigational devices-related adverse events as assessed by CTCAE v4.0
Safety outcome as measured by the incidence of investigational devices-related adverse events, event types from Day-0 (Baseline) to Day-14 (follow-up assessment)
Change in performance in a subset of The Essential Tremor Rating Assessment Scale- Activities of Daily Living (TETRAS ADL) subscales between baseline and follow-up assessment in ET participants
The Essential Tremor Rating Assessment Scale- Activities of Daily Living (TETRAS-ADL) subscale is a patient-rated scale administered by a trained interviewer that assesses the impact of tremor on day-to-day functioning, such as feeding with a spoon, drinking from a glass, pouring, using keys. Each item from the modified subscales ranges from 0 - 4, with 0 representing normal and 4 representing severely abnormal. The sum of the 4 items of TETRAS ADL subscale provide outcome score, which ranges from 0 - 16, with higher scores representing more severe ET.
Change in the Quality of Life in Essential Tremor Questionnaire (QUEST) score between baseline and follow-up assessment in ET participants
The Quality of Life in Essential Tremor Questionnaire (QUEST) was developed to specifically assess the impact of ET on health-related quality of life. The QUEST is a 30-item questionnaire comprising 5 subscales (physical, psychosocial, communication, hobbies/leisure, and work/finance) and a total score, plus 3 additional items relating to sexual function and satisfaction with tremor control and medication side effects. Each item is rated by frequency on a scale from 0 (never) to 4 (always), with higher scores indicating greater dissatisfaction or disability due to ET.
Change in Patient Global Impression- Improvement scale (PGI-I) score between baseline and follow-up assessment in ET participants
The PGI-I is a 7-point Likert-type rating scale that participants use to rate the change in severity of their ability to function due to ET. The responses to this scale range from 1 (Very much better) to 7 (Very much worse).
Change in performance in a subset of The Essential Tremor Rating Assessment Scale- performance subscales (TETRAS-PS) between baseline and follow-up assessment in ET participants.
TETARS-PS is a clinical rating scale that quantifies tremor in the head, face, voice, limbs and trunk. Items 6 (drawing an Archimedes spiral) and 7 (handwriting) of the TETRAS-PS evaluate the impact of upper limb tremor on performance. Each item from the modified subscales ranges from 0 - 4, with 0 representing normal and 4 representing severely abnormal. The sum of the TETRAS-PS items, which ranges from 0 - 8, with higher scores representing more severe ET.
Change in EQ-5D-5L score between baseline and follow-up assessment in ET participants
Health-related quality of life will be measured using the EuroQol Five Dimensions (EQ-5D). The EQ-5D-5L is a valid extension of the 3-level questionnaire. It can be defined as a standardized non-disease specific value-based instrument to describe and value health-related quality of life. The instrument consists of two components: the EQ-5D descriptive system and the EQ visual analogue scale (EQ-VAS).The first part consists of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response categories (no problems, slight problems, moderate problems, severe problems, and extreme problems). The EQ-VAS measures one's self-perceived health today on a vertical scale from 0 (worst imaginable health) to 100 (best imaginable health) on which participants have to indicate their current health.
Change in performance in a subset of the Bain and Findley ADL tasks from Day-1 to Day-14
Bain & Findley Activities of Daily Living (B&F ADL) Scale is a patient rated scale. ADL tasks included in the study are: Use a spoon to drink soup ; Hold a cup of tea ; Pour milk from a bottle or carton ; Dial a telephone ; Pick up your change ; Insert an electric plug into a socket ; Unlock your front door with a key and Write a letter. Each task will be rated on a 4-point scale (1-4): 1 = Able to do the activity without difficulty ; 2 = Able to do the activity with a little effort ; 3 = Able to do the activity with a lot of effort ; 4 = Cannot do the activity by yourself.
Change in Clinical Global Impression- Improvement scale (CGI-I) score between baseline and follow-up assessment in ET participants
The CGI-I is a 7-point Likert-type rating scale that a qualified medical personnel (ie, a clinician)will use to rate the severity of the participants' ability to function due to their ET. The responses to this scale range from 1 (Very much improved) to 7 (Very much worse).
Change in participants' experience of GyroGlove after 2-week intervention
Change in participants' experience of GyroGlove after 2-week home use will be assessed by utilising User Experience Questionnaire. Participants will complete User Experience Questionnaire form during follow-up visit.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05958030
Brief Title
GyroGlove Use in Essential Tremor Patients
Official Title
Effectiveness and Safety of GyroGlove in Stabilising Hand Tremors in Essential Tremor
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 2023 (Anticipated)
Primary Completion Date
November 2023 (Anticipated)
Study Completion Date
November 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GyroGear Ltd
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a multi-centre, single-blind, placebo-controlled trial with an open label follow up. After the baseline assessment, all participants will receive the GyroGlove for two weeks during the open label follow up part of the trial. All gloves will be retrieved and returned to GyroGear after closure of the study.
Detailed Description
All participants will attend 2 in-clinic assessment sessions (Baseline (day 0), Follow-up (day 14)) after screening visit. The baseline session will last approximately 120 minutes whilst the 2-week assessment will last approximately 60-80 minutes. At baseline assessment, participants will perform protocol-specific activities with both investigational devices (i.e. GyroGlove and Placebo).
In addition to in-clinic assessments, participants will complete self-assessments at Day -3 prior baseline visit (i.e. Day 0,) and at Day 5 and 10 from baseline (i.e. Day 0), when they started using GyroGlove at home.
All participants will be blinded at the baseline (Day 0), as assessments will be performed with GyroGlove and a placebo device in a pre-defined sequence. Each participant will act as the control for him/herself and will be blinded to the interventions order.
The sequence of interventions in the study has been pre-defined, owing to the potential for longitudinal effects of wearing the device interfering with the accurate study outcome measurement.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Essential Tremor
Keywords
Essential Tremor, Activities of Daily Living
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
All study participants will interact with both investigational device and placebo in a pre-defined sequence.
Masking
ParticipantOutcomes Assessor
Masking Description
The study is a single-blind study where study participants will be blinded to the order of both devices (investigational device and placebo) during baseline visit.
Allocation
Non-Randomized
Enrollment
30 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
No Interventional
Arm Type
No Intervention
Arm Description
Participants will perform protocol-specific tasks with no device
Arm Title
Investigational Device Arm
Arm Type
Experimental
Arm Description
GyroGlove
Arm Title
Placebo Arm
Arm Type
Placebo Comparator
Arm Description
Placebo
Intervention Type
Device
Intervention Name(s)
Placebo
Intervention Description
The placebo device consists of the same hardware as GyroGlove: aesthetically it looks the same, weight same and produces the same noise as GyroGlove. Participants will interact with Placebo on the day of baseline visit (i.e. Day 0).
Intervention Type
Device
Intervention Name(s)
GyroGlove
Intervention Description
GyroGlove is a patented wearable device containing high-performance, miniaturised, gyroscopes designed for individuals diagnosed with essential tremor. Participants will interact with GyroGlove on the day of baseline visit (i.e. Day 0), 2-week Home use and on the day of follow-up visit (i.e Day 14).
Primary Outcome Measure Information:
Title
Change from Baseline to Week- 2 (follow-up assessment) on The Essential Tremor Rating Assessment Scale (TETRAS) composite outcome score performance in ET participants
Description
The Essential Tremor Rating Assessment Scale (TETRAS) composite outcome score is the sum of modified items 2, 3, 6 & 8 of the TETRAS-ADL (Activities of Daily Living) subscale and modified items 6 - 7 of the TETRAS-PS (performance subscale). The TETRAS-ADL subscale is a patient-rated scale administered by a trained interviewer that assesses the impact of tremor on day-to-day functioning, such as feeding with a spoon, drinking from a glass, pouring, using keys etc. The TETARS-PS is a clinical rating scale that quantifies tremor in the head, face, voice, limbs and trunk. Items 6 (drawing an Archimedes spiral) and 7 (handwriting) of the TETRAS-PS evaluate the impact of upper limb tremor on performance. Each item from the modified subscales ranges from 0 - 4, with 0 representing normal and 4 representing severely abnormal. The sum of the 6 items provides the TETRAS composite outcome score, which ranges from 0 - 24, with higher scores representing more severe ET.
Time Frame
Day-0 (Baseline) and Day-14 (follow-up)
Secondary Outcome Measure Information:
Title
Change in performance in a subset of The Essential Tremor Rating Assessment Scale- performance subscales (TETRAS-PS) between GyroGlove and placebo device at baseline in ET participants
Description
TETARS-PS is a clinical rating scale that quantifies tremor in the head, face, voice, limbs and trunk. Items 6 (drawing an Archimedes spiral) and 7 (handwriting) of the TETRAS-PS evaluate the impact of upper limb tremor on performance. Each item from the modified subscales ranges from 0 - 4, with 0 representing normal and 4 representing severely abnormal. The sum of the TETRAS-PS items, which ranges from 0 - 8, with higher scores representing more severe ET.
Time Frame
Day-0 (Baseline)
Title
Change in Clinical Global Impression- Improvement scale (CGI-I) score between placebo and GyroGlove
Description
The CGI-I is a 7-point Likert-type rating scale that a qualified medical personnel (ie, a clinician)will use to rate the severity of the participants' ability to function due to their ET. The responses to this scale range from 1 (Very much improved) to 7 (Very much worse).
Time Frame
Day-0 (Baseline)
Title
Change in Patient Global Impression- Improvement scale (PGI-I) score between placebo and GyroGlove
Description
The PGI-I is a 7-point Likert-type rating scale that participants use to rate the change in severity of their ability to function due to ET. The responses to this scale range from 1 (Very much better) to 7 (Very much worse).
Time Frame
Day-0 (Baseline)
Title
Percentage of participants with Investigational devices-related adverse events as assessed by CTCAE v4.0
Description
Safety outcome as measured by the incidence of investigational devices-related adverse events, event types from Day-0 (Baseline) to Day-14 (follow-up assessment)
Time Frame
Upto Day-14
Title
Change in performance in a subset of The Essential Tremor Rating Assessment Scale- Activities of Daily Living (TETRAS ADL) subscales between baseline and follow-up assessment in ET participants
Description
The Essential Tremor Rating Assessment Scale- Activities of Daily Living (TETRAS-ADL) subscale is a patient-rated scale administered by a trained interviewer that assesses the impact of tremor on day-to-day functioning, such as feeding with a spoon, drinking from a glass, pouring, using keys. Each item from the modified subscales ranges from 0 - 4, with 0 representing normal and 4 representing severely abnormal. The sum of the 4 items of TETRAS ADL subscale provide outcome score, which ranges from 0 - 16, with higher scores representing more severe ET.
Time Frame
Day-0 (Baseline) and Day-14 (follow-up)
Title
Change in the Quality of Life in Essential Tremor Questionnaire (QUEST) score between baseline and follow-up assessment in ET participants
Description
The Quality of Life in Essential Tremor Questionnaire (QUEST) was developed to specifically assess the impact of ET on health-related quality of life. The QUEST is a 30-item questionnaire comprising 5 subscales (physical, psychosocial, communication, hobbies/leisure, and work/finance) and a total score, plus 3 additional items relating to sexual function and satisfaction with tremor control and medication side effects. Each item is rated by frequency on a scale from 0 (never) to 4 (always), with higher scores indicating greater dissatisfaction or disability due to ET.
Time Frame
Day-0 (Baseline) and Day-14
Title
Change in Patient Global Impression- Improvement scale (PGI-I) score between baseline and follow-up assessment in ET participants
Description
The PGI-I is a 7-point Likert-type rating scale that participants use to rate the change in severity of their ability to function due to ET. The responses to this scale range from 1 (Very much better) to 7 (Very much worse).
Time Frame
Day-0 (Baseline) and Day-14 (follow-up)
Title
Change in performance in a subset of The Essential Tremor Rating Assessment Scale- performance subscales (TETRAS-PS) between baseline and follow-up assessment in ET participants.
Description
TETARS-PS is a clinical rating scale that quantifies tremor in the head, face, voice, limbs and trunk. Items 6 (drawing an Archimedes spiral) and 7 (handwriting) of the TETRAS-PS evaluate the impact of upper limb tremor on performance. Each item from the modified subscales ranges from 0 - 4, with 0 representing normal and 4 representing severely abnormal. The sum of the TETRAS-PS items, which ranges from 0 - 8, with higher scores representing more severe ET.
Time Frame
Day-0 (Baseline) and Day-14 (follow-up)
Title
Change in EQ-5D-5L score between baseline and follow-up assessment in ET participants
Description
Health-related quality of life will be measured using the EuroQol Five Dimensions (EQ-5D). The EQ-5D-5L is a valid extension of the 3-level questionnaire. It can be defined as a standardized non-disease specific value-based instrument to describe and value health-related quality of life. The instrument consists of two components: the EQ-5D descriptive system and the EQ visual analogue scale (EQ-VAS).The first part consists of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response categories (no problems, slight problems, moderate problems, severe problems, and extreme problems). The EQ-VAS measures one's self-perceived health today on a vertical scale from 0 (worst imaginable health) to 100 (best imaginable health) on which participants have to indicate their current health.
Time Frame
Day-0 (Baseline) and Day-14 (follow-up)
Title
Change in performance in a subset of the Bain and Findley ADL tasks from Day-1 to Day-14
Description
Bain & Findley Activities of Daily Living (B&F ADL) Scale is a patient rated scale. ADL tasks included in the study are: Use a spoon to drink soup ; Hold a cup of tea ; Pour milk from a bottle or carton ; Dial a telephone ; Pick up your change ; Insert an electric plug into a socket ; Unlock your front door with a key and Write a letter. Each task will be rated on a 4-point scale (1-4): 1 = Able to do the activity without difficulty ; 2 = Able to do the activity with a little effort ; 3 = Able to do the activity with a lot of effort ; 4 = Cannot do the activity by yourself.
Time Frame
Day-1 to Day-14
Title
Change in Clinical Global Impression- Improvement scale (CGI-I) score between baseline and follow-up assessment in ET participants
Description
The CGI-I is a 7-point Likert-type rating scale that a qualified medical personnel (ie, a clinician)will use to rate the severity of the participants' ability to function due to their ET. The responses to this scale range from 1 (Very much improved) to 7 (Very much worse).
Time Frame
Day-0 (Baseline) and Day-14 (follow-up)
Title
Change in participants' experience of GyroGlove after 2-week intervention
Description
Change in participants' experience of GyroGlove after 2-week home use will be assessed by utilising User Experience Questionnaire. Participants will complete User Experience Questionnaire form during follow-up visit.
Time Frame
Day-14 (follow-up)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
18 years of age or older
Subject has been clinically diagnosed with ET
Has either unilateral or bilateral tremor of the hand or predominantly hand as well as forearm
Has a score of ≥ 2 in ADL activities 2, 3, 6 & 8 of the TETRAS ADL subscale (TRG, Sep 2021)
Tremor in at least one hand causing water spillage during drinking
And
Stable dosage of medications throughout the duration of the study, if applicable
Ability to speak and read in the language that the trial documentation has been translated to.
Ability to understand verbal instructions in the language that the trial documentation has been translated to.
Ability to provide written informed consent to participate in the study
Capacity to complete self-report outcome measures in the language that the trial documentation has been translated to
Exclusion Criteria:
Other possible causes of tremor, including Parkinson's disease, drug-induced, enhanced physiological tremor
Presence of tremor around the elbow and shoulder limiting participants to perform required test/procedure in the study
Has implanted electrical medical device, e.g., pacemaker, defibrillator, or deep brain stimulator
Clinically diagnosed alcohol use disorder or illicit substance use (exception medical cannabis)
Change in medication for tremor within 1 month prior to study enrolment
Change in antidepressant medication within 3 months prior to study enrolment
Has received botulinum toxin injection for hand tremor within 4 months prior to study enrolment
Has been diagnosed with any of the following conditions affecting the hand and/or arm:
Fingers/Wrist joint defects or deformities or current skeletal injuries that prevent them from wearing the glove
Hand muscular deformities or weakness, e.g.: Myotonic Dystrophy, Autosomal Recessive Muscular Dystrophy limiting participant to perform required test/procedure in the study
Skin Conditions of the hand and forearm, e.g.: Eczema, Psoriasis, Extreme Skin Sensitivity
Growth or Development Defects of the hand, including but not limited to, Brittle Bone Disease, Triphalangeal Thumb.
Previous thalamotomy procedure, including stereotactic thalamotomy, gamma knife radio surgical thalamotomy, and focused ultrasound for the treatment of tremor.
Neurological conditions aside from essential tremor that may affect the conduct of the study
Peripheral neuropathy affecting the upper extremity
Are participating or have participated in any interventional clinical trial or study in the last 30 days which may confound the results of this study, unless approved by the Sponsor
Inability to follow simple instructions
Pregnancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Faii Ong
Phone
+44 2045773038
Email
clinical@gyrogear.co
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Richard Walker
Organizational Affiliation
North Tyneside General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Quest Research Institute
City
Farmington Hills
State/Province
Michigan
ZIP/Postal Code
48334
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peter LeWitt
Phone
248-957-8940
Email
peter@questri.com
Facility Name
Houston Methodist Stanley H. Appel Department of Neurology
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
William Ondo
Phone
346-238-9068
Email
wondo@houstonmethodist.org
Facility Name
University of Vermont Medical Centre
City
Burlington
State/Province
Vermont
ZIP/Postal Code
05401
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
James Boyd
Phone
802-847-4589
Email
James.Boyd@uvmhealth.org
Facility Name
Addenbrooke Hospital, Cambridge University Hospital NHS Trust
City
Cambridge
State/Province
England
ZIP/Postal Code
CB2 0QQ
Country
United Kingdom
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paul Worth
Phone
01223349289
Email
paul.worth@addenbrookes.nhs.uk
Facility Name
Clinical Ageing Research Unit, Newcastle University
City
Newcastle
State/Province
England
ZIP/Postal Code
NE4 5PL
Country
United Kingdom
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicola Pavese
Phone
0191 2081264
Email
nicola.pavese@newcastle.ac.uk
Facility Name
Oxford University Hospitals NHS Foundation Trust, UK
City
Oxford
State/Province
England
ZIP/Postal Code
OX3 9DU
Country
United Kingdom
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Raj Sarangmat
Phone
07912145463
Email
Nagaraja.Sarangmat@ouh.nhs.uk
Facility Name
North Tyneside General Hospital
City
Newcastle
ZIP/Postal Code
NE29 8NH
Country
United Kingdom
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Richard Walker
Phone
07795617590
Email
Richard.Walker@northumbria-healthcare.nhs.uk
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
The study data collected during the study will be shared among study investigators in order to publish the study report at the end of the study.
Learn more about this trial
GyroGlove Use in Essential Tremor Patients
We'll reach out to this number within 24 hrs